Connective Tissue Growth Factor
CTGFproteinCTGF drives cardiac fibrosis and plaque inflammation through JCAD-dependent pro-atherogenic signaling in Type 1 MI.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleCardiac fibrosis marker and pro-atherogenic gene; downstream of JCAD pathway.
Also acts inCap degradation / rupture
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I48
C — confounder / Type-II82
A — assay feasibility68
E — evidence strength30
T1DI (composite)7
Specificity differential (R−C)-34.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Understanding aconite's anti-fibrotic effects in cardiac fibrosis.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2023 · PMID 37924690 · doi
- The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis.European heart journal · 2019 · PMID 31539914 · doi